Windows en Linux
Houdt de toets ctrl ingedrukt en draai het muiswiel omhoog of omlaag
Of houdt de toets ctrl ingedrukt en druk tegelijk op de toets + of -
Of ga rechtsboven naar instellingen en gebruik de instelling zoom
Mac
Houdt de toets command ingedrukt en druk op de toets + of -
Of ga rechtsboven naar instellingen en gebruik de instelling zoom.
Trials / Protocollen
Nieuwsbrieven
| Datum | Onderwerp | |
|---|---|---|
| september 2025 | Nieuwsbrief Trial Data Center |
ABL001/asciminib
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase| Ziektebeeld: | Chronisch myeloide leukemie (CML) |
| Behandellijn: | N.v.t. |
| Status: | Gearchiveerd |
| PI: | Dr. S.K. Klein |
ALXN1210-TMA-313
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)| Ziektebeeld: | Trombotische trombocytopenische purpura (of microangiopathieën) |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. C.L.E. Hazenberg |
AMG 701
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.J. Plattel |
AMG360
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)| Ziektebeeld: | Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
| https://research.monash.edu/en/projects/phase-3-randomized-controlled-study-of-blinatumomab-alternating-w | |
Anakinra / AFFECT 2
Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan – A randomized controlled trial| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bakker |
AVC-201-01 Car
AVC-201-01 - Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123. Please contact the PI for more information.| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. G.A. Huls |
| https://clinicaltrials.gov/study/NCT05949125 | |
BGB-3111-306
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | >= 2de lijn |
| Status: | Gepland |
| PI: | Dr. T. van Meerten |
Biomea Covalent-101
COVALENT-101: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)| Ziektebeeld: | AML (incl. APL), Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL), Diffuus grootcellig B-cel NHL, Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
Byon4413
| Ziektebeeld: | AML (incl. APL), Myelodysplastisch syndroom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. S.K. Klein |
| https://clinicaltrials.gov/study/NCT06359002 | |
Cartitude 2 / 68284528MMY2003
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
Cartitude 4 / 68284528MMY3002
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
Cartitude 5 / 68284528MMY3004
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
Cartitude-6 (EMN28/68284528MMY3005)
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and examethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
CMBG453B12301
A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)| Ziektebeeld: | Myelodysplastisch syndroom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
DALY-2
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
EFC17757/ROCKnrol-1
A randomized, double-blind, multicentre, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD).| Ziektebeeld: | Chronic graft versus host disease (cGVHD) |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Goda Choi |
| https://clinicaltrials.gov/study/NCT06143891 | |
Enhance-3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | N.v.t. |
| Status: | Tijdelijk gesloten |
| PI: | Prof. Dr. G.A. Huls |
Enhance/5F9009
A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome| Ziektebeeld: | Myelodysplastisch syndroom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
EPCORE DLBCL-2
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
GCT3013-03
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. M. Bellido |
| https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000848-57/NL | |
Get-8
A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A| Ziektebeeld: | Hemofilie A en B |
| Behandellijn: | N.v.t. |
| Status: | Gearchiveerd |
| PI: | Meijer |
HaploMUD
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trial.| Ziektebeeld: | Allogene stamceltransplantatie |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. C.W. Choi |
| Leeftijd: | 18 - 71 |
Hope-B
Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B| Ziektebeeld: | Hemofilie A en B |
| Status: | Gesloten voor inclusie |
| PI: | Meijer |
Hovon 119
Efficacy of alternating immunochemotherapy consisting of RCHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
Hovon 136
Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
Hovon 138
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute prOmyelocytic leukemia.| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
| Leeftijd: | 18 - 65 |
Hovon 140
CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP, SAKK, CANCER TRIALS IRELAND AND THE ISRAELI CLL STUDY GROUP| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bellido |
Hovon 141
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bellido |
Hovon 150 (IDH2 cohort gesloten)
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
Hovon 152
A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements| Ziektebeeld: | Non-Hodgkin lymfomen (NHL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
Hovon 155
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
Hovon 156
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
Hovon 159
A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. M. Bellido |
| https://hovon.nl/en/trials/ho159 | |
Hovon 161
| Ziektebeeld: | Non-Hodgkin lymfomen (NHL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Prof. Dr. T. van Meerten |
| https://hovon.nl/nl/trials/ho161-1 | |
Hovon 164
Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An open label phase II trial.| Ziektebeeld: | Hodgkin lymfoom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.J. Plattel |
| https://hovon.nl/nl/trials/ho164-patient | |
HOVON 165
A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. M. Belido |
| https://hovon.nl/nl/trials/ho165 | |
Hovon 169
Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease/ CaZa study| Ziektebeeld: | Cold Agglutinin Disease (CAD) |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Hilde Kooistra |
| https://hovon.nl/nl/trials/ho169-patient | |
Hovon 171
A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine (sc) in adult patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Prof. Dr. G.A. Huls |
| https://hovon.nl/nl/trials/ho171 | |
Hovon 176
| Ziektebeeld: | CNS Lymfoom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Marcel Nijland |
| https://hovon.nl/en/trials/ho176 | |
HOVON 177
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. G.A. Huls |
| https://hovon.nl/en/trials/ho177 | |
Hovon 501
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2*(* This study is now only for adult patients with newly diagnosed AML – the original study title was not changed)| Ziektebeeld: | Acute myeloïde leukemie |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. S.K. Klein |
| https://hovon.nl/en/trials/ho501-1 | |
IDeaL_LGL
Onderzoek naar klinische aspecten en moleculaire mechanismen bij large granular lymphocyte (LGL) leukemia – IDeAL studie| Ziektebeeld: | Large granular lymphocyte lymfocytose (LGL) |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. M. Bellido |
| https://onderzoekmetmensen.nl/en/trial/55452 | |
IL-6 Siltuximab aGVHD
A phase II study to assess the efficacy and tolerability of siltuximab in addition to standard of care tacrolimus and corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.| Ziektebeeld: | Acute graft versus host disease (aGVHD) |
| Behandellijn: | N.v.t. |
| Status: | Gepland |
| PI: | E.A. Ammatuna |
ISKIA / HO503
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
KT-US-982-5968
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells| Ziektebeeld: | Hematologische ziekten |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| https://www.gileadclinicaltrials.com/study?id=KT-US-982-5968 | |
LBL-Registry
A Prospective, Multicenter, Observational Study of Real-Life Current Standards of Care in Patients with lymphoblastic lymphoma including the evaluation with FDG-PET-CT scintigraphy| Ziektebeeld: | Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL) |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | dr M (Mar) Bellido |
M20-638
Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2 ) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)| Ziektebeeld: | Folliculair NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
M22-003
| Ziektebeeld: | Folliculair NHL |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Marcel Nijland |
| https://www.adventhealth.com/institute/adventhealth-research-institute/clinical-cancer-research/clinical-trials/4235-m22-003-a-phase-3-multicenter-randomized-open-label-trial-evaluate-safety-and-efficacy-epcoritamab | |
MajesTEC-3 / 64007957MMY3001
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.J. Plattel |
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| https://ichgcp.net/nl/eu-clinical-trials-registry/trial/2021-002531-27/gr | |
MajesTEC-9 / 64007957MMY3006
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| https://clinicaltrials.gov/study/NCT05572515 | |
MGD006-01
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Gearchiveerd |
| PI: | Prof. Dr. G.A. Huls |
| Leeftijd: | 18 - 65 |
MK3543-006 ET
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants with Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.| Ziektebeeld: | Essentiele trombocytose (ET) |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Emanuele Ammatuna |
| https://clinicaltrials.gov/study/NCT06079879?term=mk3543&rank=6 | |
MP0533-CP101
A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)| Ziektebeeld: | AML (incl. APL), Myelodysplastisch syndroom |
| Behandellijn: | >= 2de lijn |
| Status: | Tijdelijk gesloten |
MPOH08 – MaaT033 Phoebus
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications| Ziektebeeld: | Patients with a planned alloHCT |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. L. Morsink |
| https://clinicaltrials.gov/study/NCT05762211?term=phoebus&rank=1 | |
PEARL-NL
Prospective Evaluation of Aplastic anemia: Real Life outcomes in the Netherlands| Ziektebeeld: | Aplastische anemie |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Saskia Klein |
| https://www.lumc.nl/afdelingen/hematologie/ziektes-en-aandoeningen/aplastische-anemie/ | |
Prothena AFFIRM-AL / NEOD001-301
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis| Ziektebeeld: | Amyloïdose |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| Leeftijd: | 18 - 75 |
RADAR
A randomized phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma.| Ziektebeeld: | Hodgkin lymfoom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. T.W. Plattel |
| Leeftijd: | 16 - 69 |
| https://clinicaltrials.gov/study/NCT04685616?term=NCT04685616&rank=1 | |
SAR443579 – TCD17197
An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high riskmyelodysplasia (HR-MDS)| Ziektebeeld: | Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL), AML (incl. APL), Myelodysplastisch syndroom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
| Https://clinicaltrials.gov/study/NCT05086315 | |
Servier-S095031-178
| Ziektebeeld: | Acute myeloïde leukemie |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Gerwin Huls |
| https://clinicaltrials.gov/study/NCT06465953?term=S095031-178&rank=1 | |
Shine
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | 1ste lijn |
| Status: | Gearchiveerd |
| PI: | Dr. M. Nijland |
Taurus/EMN33/54767414MMY2089
A Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (D-VRd) Induction and Either an Autologous Stem Cell Transplantation (ASCT) and D-VRd Consolidation or D-VRd followed by Teclistamab in Combination with Talquetamab.| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
Trispecific Antibody (79635322MMY1001)
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| https://onderzoekmetmensen.nl/en/trial/53500 | |
Trispecific Combo 79635322MMY1002
A Phase 1b Study of JNJ-79635322 in Combination with Daratumumab or Pomalidomide for Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn, 1ste lijn |
| Status: | Open |
| PI: | Dr. W.J. Plattel |
| https://clinicaltrials.gov/study/NCT06768489?term=79635322MMY1002&rank=1 | |
XPORT-MF-034-Karyopharm
A Phase 1/3 study to evaluate the efficacy and safety of Selinexor, a selective inhibitor of nuclear export, in combination with Ruxolitinib in treatment-naïve patients with myelofibrosis.| Ziektebeeld: | Primaire myelofibrose |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Emanuele Ammatuna |
| https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.7063 | |
ZUMA-7
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
ZUMA23
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)| Ziektebeeld: | High-Grade B-Cell Lymphoma (HGBCL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| https://clinicaltrials.gov/study/NCT05605899 | |